Patent · US Active

Pharmaceutical formulations of desmopressin

US10307459B2 · kind B2 · utility

2Cited by

92References

15Claims

0Family size

Assignee

Ferring B.V. · NL

Inventors

Anders Nilsson · Västerås, SE
Hans Lindner · Leichlingen, DE
Jørgen Wittendorff · Copenhagen, DK

Key dates

Filing date	Jan 26, 2018
Grant date	Jun 4, 2019
Priority date	—
Expiry date	Jan 26, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2095
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.